Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Viard, J P
D'Arminio Monforte, A
Rockstroh, J K
Lundgren, J D
MetadataShow full item record
CitationEstablishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA. 2019, 20(4):264-273 HIV Med
AbstractThe aim of the study was to establish a methodology for evaluating the hepatitis C continuum of care in HIV/hepatitis C virus (HCV)-coinfected individuals and to characterize the continuum in Europe on 1 January 2015, prior to widespread access to direct-acting antiviral (DAA) therapy. Stages included in the continuum were as follows: anti-HCV antibody positive, HCV RNA tested, currently HCV RNA positive, ever HCV RNA positive, ever received HCV treatment, completed HCV treatment, follow-up HCV RNA test, and cure. Sustained virological response (SVR) could only be assessed for those with a follow-up HCV RNA test and was defined as a negative HCV RNA result measured > 12 or 24 weeks after stopping treatment. Numbers and percentages for the stages of the HCV continuum of care were as follows: anti-HCV positive (n = 5173), HCV RNA tested (4207 of 5173; 81.3%), currently HCV RNA positive (3179 of 5173; 61.5%), ever HCV RNA positive (n = 3876), initiated HCV treatment (1693 of 3876; 43.7%), completed HCV treatment (1598 of 3876; 41.2%), follow-up HCV RNA test to allow SVR assessment (1195 of 3876; 30.8%), and cure (629 of 3876; 16.2%). The proportion that achieved SVR was 52.6% (629 of 1195). There were significant differences between regions at each stage of the continuum (P < 0.0001). In the proposed HCV continuum of care for HIV/HCV-coinfected individuals, we found major gaps at all stages, with almost 20% of anti-HCV-positive individuals having no documented HCV RNA test and a low proportion achieving SVR, in the pre-DAA era.
DescriptionTo access publisher's full text version of this article click on the hyperlink below
- Comparison of the Hepatitis C Continua of Care Between Hepatitis C Virus/HIV Coinfected and Hepatitis C Virus Mono-Infected Patients in Two Treatment Eras During 2008-2015.
- Authors: Roberson JL, Lagasca AM, Kan VL
- Issue date: 2018 Feb
- Hepatitis C treatment uptake and response among human immunodeficiency virus/hepatitis C virus-coinfected patients in a large integrated healthcare system.
- Authors: Lam JO, Hurley LB, Chamberland S, Champsi JH, Gittleman LC, Korn DG, Lai JB, Quesenberry CP Jr, Ready J, Saxena V, Seo SI, Witt DJ, Silverberg MJ, Marcus JL
- Issue date: 2019 Jun
- Hepatitis C and human immunodeficiency virus coinfection in the era of direct-acting antiviral agents: No longer a difficult-to-treat population.
- Authors: Sikavi C, Chen PH, Lee AD, Saab EG, Choi G, Saab S
- Issue date: 2018 Mar
- Uptake of hepatitis C virus treatment in HIV/hepatitis C virus-coinfected patients across Europe in the era of direct-acting antivirals.
- Authors: Peters L, Laut K, Resnati C, Del Campo S, Leen C, Falconer K, Trofimova T, Paduta D, Gatell J, Rauch A, Lacombe K, Domingo P, Chkhartishvili N, Zangerle R, Matulionyte R, Mitsura V, Benfield T, Zilmer K, Khromova I, Lundgren J, Rockstroh J, Mocroft A, EuroSIDA Study Group.
- Issue date: 2018 Sep 10
- Latest pharmacotherapy options for treating hepatitis C in HIV-infected patients.
- Authors: Macías J, Neukam K, Merchante N, Pineda JA
- Issue date: 2014 Sep